Table 1.

Desirable Characteristics for Compendia Used As References for Off-Label Uses of Anticancer Drugs and Biologicals^2(p60)

Extensive breadth of listings Quick processing from application for inclusion to listing Detailed description of the evidence reviewed for every individual listing Use of pre-specified published criteria for weighing evidence Use of prescribed published process for making recommendations Publicly transparent process for evaluating therapies Explicit “Not recommended” listing when validated evidence is appropriate Explicit listing and recommendations regarding therapies, including sequential use or combination in relation to other therapies Explicit “Equivocal” listing when validated evidence is equivocal Process for public identification and notification of potential conflicts of interest of the compendia's parent and sibling organizations, reviewers, and committee members, with an established procedure to manage recognized conflicts